US · CTEV · MEDICAL - HEALTHCARE INFORMATION SERVICES
Claritev Corporation (CTEV) intrinsic value and stock valuation
$18.28as of 2026-11-21 · Mkt cap 555.59M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Claritev Corporation DCF and intrinsic value
InvestorsCraft values CTEV with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from CTEV’s statements →
Claritev Corporation Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2018–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $965.4M | $930.6M | $961.5M | $1.08B | $1.12B |
| Operating income | $45.1M | -$-1.39B | $162M | -$-362.73M | $386.1M |
| Net income | -$-284.28M | -$-1.65B | -$-91.7M | -$-572.91M | $102.1M |
| EPSd | -$-17.3M | -$-101.91M | -$-5.69M | -$-35.87M | $6.27M |
| Operating cash flow | $117.3M | $107.6M | $171.7M | $372.4M | $404.7M |
| Capital expenditure | -$-129.6M | -$-118.12M | -$-108.85M | -$-89.73M | -$-84.59M |
| Free cash flow | -$-12.28M | -$-10.51M | $62.9M | $282.6M | $320.1M |
| Total assets | $4.89B | $5.15B | $6.96B | $7.37B | $8.22B |
| Total debt | $4.63B | $4.54B | $4.57B | $4.78B | $4.93B |
| Net debt | $4.62B | $4.52B | $4.5B | $4.45B | $4.74B |
| Total equity | -$-167.18M | $84M | $1.71B | $1.79B | $2.34B |
| Cash and short-term investments | $16.8M | $16.9M | $71.6M | $334.1M | $185.3M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $965.4M | $930.6M | $961.5M | $1.08B | $1.12B |
| Cost of revenue | $698.8M | $239.4M | $235.5M | $204.1M | $175.3M |
| Gross profit | $266.6M | $691.2M | $726.1M | $875.6M | $942.3M |
| Research and development expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Selling, general and administrative expenses | $221.5M | $160.2M | $136M | $132.1M | $151.1M |
| Other expenses | $0.00 | $1.92B | $428.1M | $1.11B | $405.1M |
| Operating expenses | $221.5M | $2.08B | $564.1M | $1.24B | $556.2M |
| Cost and expenses | $920.4M | $2.32B | $799.5M | $1.44B | $731.5M |
| Interest income | $1.56M | $3.13M | $8.23M | $3.5M | $30K |
| Interest expense | $400.1M | $326.4M | $333.2M | $303.4M | $267.5M |
| Depreciation and amortization | $448.5M | $436.4M | $425.8M | $415.7M | $412.1M |
| Ebitda | $475.4M | -$-1.01B | $651.9M | $158.3M | $815M |
| Operating income | $45.1M | -$-1.39B | $162M | -$-362.73M | $386.1M |
| Total other income/expenses, net | -$-418.14M | -$-380.78M | -$-269.04M | -$-198.01M | -$-250.67M |
| Income before tax | -$-373.08M | -$-1.77B | -$-107.06M | -$-560.74M | $135.5M |
| Income tax expense | -$-88.8M | -$-124.88M | -$-15.36M | $12.2M | $33.4M |
| Net income | -$-284.28M | -$-1.65B | -$-91.7M | -$-572.91M | $102.1M |
| Weighted average shares outstanding | $16.4M | $16.2M | $16.1M | $16M | $16.3M |
| Weighted average diluted shares outstanding | $16.4M | $16.2M | $16.1M | $16M | $16.3M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $16.8M | $16.9M | $71.6M | $334.1M | $185.3M |
| Net receivables | $138.2M | $111.6M | $84.8M | $78.9M | $99.9M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $224.4M | $175.5M | $193.6M | $446.7M | $319.3M |
| Property, plant and equipment, net | $340.3M | $308.8M | $287.1M | $257.1M | $243.3M |
| Goodwill and intangible assets | $4.29B | $4.63B | $6.46B | $6.65B | $7.65B |
| Long-term investments | $0.00 | $15M | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $4.66B | $4.98B | $6.77B | $6.92B | $7.9B |
| Total assets | $4.89B | $5.15B | $6.96B | $7.37B | $8.22B |
| Accounts payable | $60.5M | $86.3M | $19.6M | $13.3M | $13M |
| Short-term debt | $19.4M | $17.6M | $18M | $19.6M | $20.1M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $261.4M | $213.8M | $166.7M | $175.8M | $141.9M |
| Long-term debt | $4.61B | $4.52B | $4.55B | $4.76B | $4.91B |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $4.79B | $4.85B | $5.09B | $5.4B | $5.73B |
| Capital lease obligations | $16.2M | $18.2M | $21.9M | $27.3M | $33.6M |
| Total liabilities | $5.06B | $5.07B | $5.26B | $5.58B | $5.88B |
| Common stock | $0.00 | $0.00 | $0.00 | $70K | $70K |
| Retained earnings | -$-2.43B | -$-2.15B | -$-499.31M | -$-347.8M | $225.1M |
| Accumulated other comprehensive income (loss) | -$-4.17M | -$-5.06M | -$-11.78M | $0.00 | $0.00 |
| Total equity | -$-167.18M | $84M | $1.71B | $1.79B | $2.34B |
| Total investments | $0.00 | $15M | $0.00 | $0.00 | $0.00 |
| Total debt | $4.63B | $4.54B | $4.57B | $4.78B | $4.93B |
| Net debt | $4.62B | $4.52B | $4.5B | $4.45B | $4.74B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-284.28M | -$-1.65B | -$-91.7M | -$-572.91M | $102.1M |
| Depreciation and amortization | $445.4M | $436.4M | $425.8M | $415.7M | $424.3M |
| Stock-based compensation | $27.8M | $26.6M | $18M | $16.7M | $18M |
| Change in working capital | -$-28.87M | -$-13.67M | -$-21.91M | $55.3M | -$-46.68M |
| Accounts receivable | -$-26.57M | -$-13.2M | $4.4M | $21M | -$-33.83M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | -$-25.86M | $42.2M | $5.58M | $34.4M | $7.71M |
| Net cash provided by operating activities | $117.3M | $107.6M | $171.7M | $372.4M | $404.7M |
| Investments in property, plant and equipment | -$-129.6M | -$-118.12M | -$-108.85M | -$-89.73M | -$-84.59M |
| Acquisitions, net | $0.00 | $0.00 | -$-140.94M | $0.00 | -$-149.43M |
| Net cash used for investing activities | -$-121.02M | -$-118.12M | -$-249.79M | -$-104.45M | -$-228.38M |
| Common stock issued | $1.74M | $0.00 | $510K | $0.00 | $0.00 |
| Common stock repurchased | $0.00 | -$-10.37M | -$-15.22M | -$-100M | -$-103.79M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $2.36M | -$-41.31M | -$-180.99M | -$-115.74M | -$-114.68M |
| Net change in cash | -$-1.33M | -$-51.82M | -$-259.06M | $152.2M | $61.6M |
| Cash at end of period | $28.3M | $29.7M | $81.5M | $340.6M | $188.4M |
| Operating cash flow | $117.3M | $107.6M | $171.7M | $372.4M | $404.7M |
| Capital expenditure | -$-129.6M | -$-118.12M | -$-108.85M | -$-89.73M | -$-84.59M |
| Free cash flow | -$-12.28M | -$-10.51M | $62.9M | $282.6M | $320.1M |
Line items
Line items
Line items
About Claritev Corporation
Claritev Corporation, together with its affiliated companies, provides advanced data analytics and technology-enabled services focused on cost management, payment optimization, and revenue assurance for the healthcare sector across the United States. The company offers a suite of services designed to reduce medical expenses. This includes analytics-driven solutions that utilize sophisticated algorithms and data insights to pinpoint billing overcharges, subsequently assisting with or recommending appropriate reimbursement negotiations. Additionally, their network-focused services secure discounted rates through contracts with healthcare providers and provide outsourced administration for these provider networks. Claritev also specializes in payment and revenue integrity, identifying and removing erroneous or unwarranted charges processed during claims, while simultaneously working to identify, recover, and safeguard underpaid premium amounts. Furthermore, their data and decision science offerings encompass a range of solutions that apply modern data science methodologies—including descriptive, predictive, and prescriptive analytics—to refine benefit plan structures, aid strategic decision-making, enhance patient clinical results, and ultimately lower overall healthcare costs. The company also handles business-to-business healthcare payment processing and other related services. Their diverse clientele includes major national and regional insurance carriers, Blue Cross and Blue Shield organizations, various provider-sponsored and independent health plans, third-party administrators (TPAs), self-insured health plans, property and casualty insurers, bill review firms, and other entities involved in the claims settlement process. Established in 1980 and headquartered in New York, New York, Claritev Corporation was previously known as MultiPlan Corporation before officially adopting its current name in February 2025.
- CEO
- Travis S. Dalton
- Employees
- 3K
- Beta
- 0.70
Explore
Frequently asked questions
What is the intrinsic value of Claritev Corporation (CTEV)?
Claritev Corporation (CTEV) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is CTEV undervalued?
CTEV trades at a price of $18.28 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.